Monopar Therapeutics(MNPR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

MNPR Monopar Therapeutics

Closed 11-13 16:00:00 EST

72.00

-0.68

-0.94%

盘后72.00

+0.000.00%

19:55 EST

High73.67	Low67.70	Vol203.86K
Open72.93	D1 Closing72.68	Amplitude8.21%
Mkt Cap487.93M	Tradable Cap326.33M	Total Shares6.78M
T/O14.43M	T/O Rate4.50%	Tradable Shares4.53M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"MNPR","market":"US","secType":"STK","nameCN":"Monopar Therapeutics","latestPrice":72,"timestamp":1794603600000,"preClose":72.68,"halted":0,"volume":203862,"hourTrading":{"tag":"盘后","latestPrice":72,"preClose":72,"latestTime":"19:55 EST","volume":1188,"amount":85585.2253,"timestamp":1794617704850,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.009356081452944507,"floatShares":4532400,"shares":6776773,"eps":-2.180383,"marketStatus":"Closed","change":-0.68,"latestTime":"11-13 16:00:00 EST","open":72.93,"high":73.67,"low":67.7,"amount":14429741.73642,"amplitude":0.082141,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.180383,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1794819600000},"marketStatusCode":5,"adr":0,"listingDate":1576731600000,"exchange":"NASDAQ","adjPreClose":72.68,"preHourTrading":{"tag":"盘前","latestPrice":71.61,"preClose":72.68,"latestTime":"09:27 EST","volume":158,"amount":11587.631519999999,"timestamp":1794580030922,"change":-1.07,"changeRate":-0.014722,"amplitude":0.052972},"postHourTrading":{"tag":"盘后","latestPrice":72,"preClose":72,"latestTime":"19:55 EST","volume":1188,"amount":85585.2253,"timestamp":1794617704850,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.310571},"requestUrl":"/m/hq/s/MNPR/wiki","defaultTab":"wiki","newsList":[{"id":"2683574540","title":"Monopar Therapeutics Raised to Overweight from Neutral by Cantor Fitzgerald","url":"https://stock-news.laohu8.com/highlight/detail?id=2683574540","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2683574540?lang=en_us&edition=fundamental","pubTime":"2026-11-13 18:45","pubTimestamp":1794566700,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MNPR/analyst-ratings","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MNPR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2683519429","title":"Cantor upgrades Monopar Therapeutics on recent pullback, added clarity","url":"https://stock-news.laohu8.com/highlight/detail?id=2683519429","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2683519429?lang=en_us&edition=fundamental","pubTime":"2026-11-13 02:20","pubTimestamp":1794507624,"startTime":"0","endTime":"0","summary":"Cantor Fitzgerald upgraded Monopar Therapeutics (MNPR) to Overweight from Neutral with an unchanged price target of $119 after the company reported...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cantor-upgrades-monopar-therapeutics-on-recent-pullback-added-clarity-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cantor-upgrades-monopar-therapeutics-on-recent-pullback-added-clarity-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MNPR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2683478519","title":"Monopar Therapeutics upgraded to Overweight from Neutral at Cantor Fitzgerald","url":"https://stock-news.laohu8.com/highlight/detail?id=2683478519","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2683478519?lang=en_us&edition=fundamental","pubTime":"2026-11-13 02:15","pubTimestamp":1794507328,"startTime":"0","endTime":"0","summary":"Cantor Fitzgerald upgraded Monopar Therapeutics (MNPR) to Overweight from Neutral with a $119 price target Published first on TheFly – the ultimate...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/monopar-therapeutics-upgraded-to-overweight-from-neutral-at-cantor-fitzgerald-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/monopar-therapeutics-upgraded-to-overweight-from-neutral-at-cantor-fitzgerald-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MNPR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682513567","title":"Monopar Therapeutics Inc. Reports Results for the Quarter Ended September 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2682513567","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2682513567?lang=en_us&edition=fundamental","pubTime":"2026-11-12 23:49","pubTimestamp":1794498599,"startTime":"0","endTime":"0","summary":"Monopar Therapeutics Inc. reports results for the quarter ended September 30 - Earnings SummaryMonopar Therapeutics Inc.MNPR.OQreported a quarterly adjusted loss of 72 cents per share for the quarter ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261112:nL5N46T254:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MNPR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682594562","title":"Monopar Therapeutics reports Q3 EPS (72c), consensus (85c)","url":"https://stock-news.laohu8.com/highlight/detail?id=2682594562","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2682594562?lang=en_us&edition=fundamental","pubTime":"2026-11-12 21:36","pubTimestamp":1794490578,"startTime":"0","endTime":"0","summary":"The company said, “Cash, cash equivalents and investments as of September 30, 2026, were $129.4 million. Monopar expects its current funds to suppo...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/monopar-therapeutics-reports-q3-eps-72c-consensus-85c-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/monopar-therapeutics-reports-q3-eps-72c-consensus-85c-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MNPR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682591647","title":"Monopar Therapeutics Q3 EPS $(0.72) Beats $(0.80) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2682591647","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2682591647?lang=en_us&edition=fundamental","pubTime":"2026-11-12 21:22","pubTimestamp":1794489776,"startTime":"0","endTime":"0","summary":"Monopar Therapeutics (NASDAQ:MNPR) reported quarterly losses of $(0.72) per share which beat the analyst consensus estimate of $(0.80) by 10 percent. This is a 50 percent decrease over losses of $(0.48) per share from","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/11/63183054/monopar-therapeutics-q3-eps-0-72-beats-0-80-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MNPR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682596084","title":"Monopar Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2682596084","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2682596084?lang=en_us&edition=fundamental","pubTime":"2026-11-12 21:00","pubTimestamp":1794488405,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261112:nTUAC8M8BG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MNPR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682255383","title":"Monopar Phase 3 Data Show Persistent Disease Burden in Treated Wilson Disease Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2682255383","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2682255383?lang=en_us&edition=fundamental","pubTime":"2026-11-09 21:02","pubTimestamp":1794229348,"startTime":"0","endTime":"0","summary":"Monopar Phase 3 Data Show Persistent Disease Burden in Treated Wilson Disease PatientsMonopar Therapeutics presented Phase 3 FoCus baseline findings and ALXN1840 safety data at AASLD’s The Liver Meeti","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261109:nNDL5ST6jl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2095319765.USD","IE00BQXX3C00.GBP","BCDF","SG9999014021.USD","SG9999014039.USD","SG9999014013.SGD","BK4588","SG9999014005.SGD","IE00BN0W2W23.USD","LU2210149790.SGD","IE00BQXX3F31.USD","BK4139","BK4585","IE00BKPKM429.USD","IE00B64PRP62.GBP","IE00BN0W2V16.EUR","IE00BN0W2T93.GBP","NDAQ","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","MNPR","BK4112","IE00BQXX3D17.EUR","LU0314104364.USD","LU2210150020.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681090140","title":"Monopar Therapeutics Director Kim R. Tsuchimoto Reports Sale of $290,061.75 in Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2681090140","media":"Reuters","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681090140?lang=en_us&edition=fundamental","pubTime":"2026-11-05 09:15","pubTimestamp":1793841356,"startTime":"0","endTime":"0","summary":"Monopar Therapeutics Director Kim R. Tsuchimoto Reports Sale of $290,061.75 in Common SharesMonopar Therapeutics director Kim R. Tsuchimoto sold 4,090 common shares on November 2 and 4, 2026.Reported ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261105:nNDL4Rh1Nv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Monopar Therapeutics Director Kim R. Tsuchimoto Reports Sale of $290,061.75 in Common Shares","news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MNPR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675599050","title":"This Monopar Therapeutics Insider Reduced Their Stake By 37%","url":"https://stock-news.laohu8.com/highlight/detail?id=2675599050","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675599050?lang=en_us&edition=fundamental","pubTime":"2026-10-16 18:42","pubTimestamp":1792147339,"startTime":"0","endTime":"0","summary":"Viewing insider transactions for Monopar Therapeutics Inc.'s ( NASDAQ:MNPR ) over the last year, we see that insiders...","market":"nz","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice1-card/1788937617532","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice1-card/1788937617532"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mnpr/monopar-therapeutics/news/this-monopar-therapeutics-insider-reduced-their-stake-by-37","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mnpr/monopar-therapeutics/news/this-monopar-therapeutics-insider-reduced-their-stake-by-37","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["MNPR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673008215","title":"Monopar Therapeutics Director Christopher M. Starr Disposes of USD 672,243 in Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2673008215","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673008215?lang=en_us&edition=fundamental","pubTime":"2026-10-06 05:44","pubTimestamp":1791236649,"startTime":"0","endTime":"0","summary":"Monopar Therapeutics director Christopher M. Starr disposes of USD 672,243 in common sharesDirector Christopher M. Starr cut his direct stake in Monopar Therapeutics to 5,173 common shares on Oct. 1, ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261005:nNDL1nxd2v:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Monopar Therapeutics Director Christopher M. Starr Disposes of USD 672,243 in Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MNPR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669114353","title":"H.C. Wainwright Reaffirms Their Buy Rating on Monopar Therapeutics Inc (MNPR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2669114353","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669114353?lang=en_us&edition=fundamental","pubTime":"2026-09-22 17:45","pubTimestamp":1790070356,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Andres Y. Maldonado maintained a Buy rating on Monopar Therapeutics Inc yesterday and set a price target of $125.00. The co...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-reaffirms-their-buy-rating-on-monopar-therapeutics-inc-mnpr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-reaffirms-their-buy-rating-on-monopar-therapeutics-inc-mnpr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MNPR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666523892","title":"Monopar Therapeutics Inc. : Barclays Raises Target Price to $145 from $128","url":"https://stock-news.laohu8.com/highlight/detail?id=2666523892","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666523892?lang=en_us&edition=fundamental","pubTime":"2026-09-11 17:45","pubTimestamp":1789119903,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260911:nFWN4530GP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MNPR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666541939","title":"U.S. Research Roundup- Adobe, Chewy, Mosaic","url":"https://stock-news.laohu8.com/highlight/detail?id=2666541939","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666541939?lang=en_us&edition=fundamental","pubTime":"2026-09-11 15:09","pubTimestamp":1789110591,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP- Adobe, Chewy, MosaicSept 11 (Reuters)-Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Adobe, Chewy and Mosaic","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260911:nL4N4530JP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALK","CHWY","PAYX","PLTI","AALG","LEGN","OMDA","ORCU","AEO","MOS","LH","AVAV","EMN","OLN","AAL","LUV","MEDI","AXTA","MNPR","ELF","APD","AVXX","PPG","CF","CE","ORCL","PLTR","PLTW","DAL","ULCC","CTVA","SPLTRmain","UAL","IFF","AIPI","HUN","OVID","SHW","FMC","JBLU","ADBE","ATO","PBJ","ORCS","RPM","ALGT","KROP","VVV","ONB","DNTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662039325","title":"Monopar Therapeutics Director Raymond Anderson Sells USD 349,125 of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2662039325","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662039325?lang=en_us&edition=fundamental","pubTime":"2026-08-28 06:28","pubTimestamp":1787869711,"startTime":"0","endTime":"0","summary":"Monopar Therapeutics director Raymond Anderson sells USD 349,125 of common sharesDirector Raymond Anderson sold 3,142 Monopar Therapeutics common shares on Aug. 25, 2026 at prices around USD 110.04 to","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nNDL8jpWGX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Monopar Therapeutics Director Raymond Anderson Sells USD 349,125 of Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MNPR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660742856","title":"Monopar Names Jeffrey D. Kent Executive Vice President, Head of Medical Affairs","url":"https://stock-news.laohu8.com/highlight/detail?id=2660742856","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660742856?lang=en_us&edition=fundamental","pubTime":"2026-08-19 20:03","pubTimestamp":1787141025,"startTime":"0","endTime":"0","summary":"Monopar names Jeffrey D. Kent executive vice president, head of medical affairsMonopar named Jeffrey D. Kent as executive vice president, head of medical affairs, effective Sept. 1, 2026.Role centers ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260819:nNDL7gLTvP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MNPR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660288034","title":"Monopar Appoints Jeffrey D. Kent, M.d., as Executive Vice President, Head of Medical Affairs; Announces Two Alxn1840 Presentations at Aasld – the Liver Meeting® 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2660288034","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660288034?lang=en_us&edition=fundamental","pubTime":"2026-08-19 20:00","pubTimestamp":1787140803,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260819:nTUA69GYB0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MNPR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660800144","title":"Morgan Stanley Keeps Their Buy Rating on Monopar Therapeutics Inc (MNPR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2660800144","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660800144?lang=en_us&edition=fundamental","pubTime":"2026-08-17 20:57","pubTimestamp":1786971477,"startTime":"0","endTime":"0","summary":"In a report released today, Maxwell Skor from Morgan Stanley maintained a Buy rating on Monopar Therapeutics Inc, with a price target of $130.00. S...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/morgan-stanley-keeps-their-buy-rating-on-monopar-therapeutics-inc-mnpr-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/morgan-stanley-keeps-their-buy-rating-on-monopar-therapeutics-inc-mnpr-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MNPR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659614261","title":"Monopar Therapeutics Shares Drop After Downgrade From Cantor Fitzgerald","url":"https://stock-news.laohu8.com/highlight/detail?id=2659614261","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659614261?lang=en_us&edition=fundamental","pubTime":"2026-08-14 02:27","pubTimestamp":1786645641,"startTime":"0","endTime":"0","summary":"Monopar Therapeutics  shares were down 4.2% in afternoon trading on Thursday after Cantor Fitzgerald downgraded the company's stock to neutral from overweight and adjusted the price target to $119 from $109.Trading volume stood at more than 115,000 shares against a daily average of around 222,000.Price: 110.13, Change: -4.78, Percent Change: -4.16","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MNPR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659633831","title":"Monopar Therapeutics is Maintained at Overweight by Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2659633831","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659633831?lang=en_us&edition=fundamental","pubTime":"2026-08-13 22:31","pubTimestamp":1786631460,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MNPR/analyst-ratings","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MNPR"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.monopartx.com","stockEarnings":[{"period":"1week","weight":0.0812},{"period":"1month","weight":0.0083},{"period":"3month","weight":-0.357},{"period":"6month","weight":0.2263},{"period":"1year","weight":-0.1199},{"period":"ytd","weight":0.113}],"compareEarnings":[{"period":"1week","weight":0.0329},{"period":"1month","weight":-0.0269},{"period":"3month","weight":-0.0248},{"period":"6month","weight":0.0243},{"period":"1year","weight":0.1079},{"period":"ytd","weight":0.1103}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":0.22612},{"month":2,"riseRate":0.285714,"avgChangeRate":0.090755},{"month":3,"riseRate":0.142857,"avgChangeRate":-0.182533},{"month":4,"riseRate":0.285714,"avgChangeRate":-0.03289},{"month":5,"riseRate":0.285714,"avgChangeRate":-0.037743},{"month":6,"riseRate":0.714286,"avgChangeRate":0.099323},{"month":7,"riseRate":0.285714,"avgChangeRate":-0.016558},{"month":8,"riseRate":0.142857,"avgChangeRate":-0.131595},{"month":9,"riseRate":0.285714,"avgChangeRate":0.373822},{"month":10,"riseRate":0.428571,"avgChangeRate":0.175221},{"month":11,"riseRate":0.714286,"avgChangeRate":0.045081},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.031256}],"exchange":"NASDAQ","name":"Monopar Therapeutics","nameEN":"Monopar Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Monopar Therapeutics(MNPR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Monopar Therapeutics(MNPR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Monopar Therapeutics,MNPR,Monopar Therapeutics股票,Monopar Therapeutics股票老虎,Monopar Therapeutics股票老虎国际,Monopar Therapeutics行情,Monopar Therapeutics股票行情,Monopar Therapeutics股价,Monopar Therapeutics股市,Monopar Therapeutics股票价格,Monopar Therapeutics股票交易,Monopar Therapeutics股票购买,Monopar Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Monopar Therapeutics(MNPR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Monopar Therapeutics(MNPR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}